U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder

Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.

"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys" with early, active Cerebral Adrenoleukodystrophy (CALD), the company said in a statement, saying CALD is a "devastating and fatal neurodegenerative disease."

 

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)